NCT05995405Phase 3Active not recruiting

Safety and Tolerability of GTX-104 Compared with Oral Nimodipine in Patients with ASAH

Study sponsor: Grace Therapeutics Inc. · GRCE

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2024-12Estimated

Enrollment · participants100Estimated

Source updated2024-10-01Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Aneurysmal Subarachnoid Hemorrhage (aSAH)

Treatments or interventions studied

GTX-104Drug
Nimotop 30 MG Oral CapsuleDrug

Primary outcomes · main study measures

measure: Incidence (% or proportion) of subjects with at least one episode of clinically significant hypotension with a reasonable possibility that GTX-104/oral nimodipine caused the event, according to the Endpoint Adjudication Committee.; description: Hypotension events requiring medical treatment; timeFrame: 90 days

History coverage

Imported research includes version dates later than the current official API record (2024-10-01). Disputed observations are retained for audit and excluded from trusted change feeds and sponsor statistics. Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history